I think at this point it's tough to overstate the
Post# of 148162
If you had told me 2 years ago that 2 years later we would essentially not be any closer to an FDA approval...no way would I have believed you. Sure, we've made progress in some respects, but no way do we seem closer to an approval.
It's sad for investors but hopefully that can change. Patients being denied a safer therapy for multiple indications is really a travesty because damage has already been done in many cases by not having leronlimab approved or as an open label option.